VERQUVO provides a straight forward dose adjustment schedule to achieve the desired 10mg target dose.1
- Start at 2.5mg once daily taken with food.1
- Double dose approximately every 2 weeks, as tolerated.1
- Until the target maintenance dose of 10mg once daily is achieved.1
- Dose adjustment can be achieved in four weeks, but for some patients up-titration may take longer.1
90% of patients in the VICTORIA study who received VERQUVO achieved the target dose of 10mg.1
Importantly, no dosage adjustment of VERQUVO is required for patients with renal impairment (eGFR ≥ 15 mL/min/1.73m2, without dialysis).
This means, VERQUVO can provide a solution for patients who have experienced a worsening heart failure (HF) event and can be used across a broad range of patients with chronic HF, regardless of background therapies.1
Remember, after a worsening HF event, patients deteriorate further and need your urgent attention.
A safety profile you can depend on
Adopt a treatment with a well-tolerated safety profile that can be used across a broad range of patients with chronic HF, regardless of background therapy.
Are you worried about hypotension?
Does your patient with Type 2 Diabetes have impaired renal function or other comorbid conditions?
VERQUVO is well tolerated in patients with chronic HF following a worsening HF event.
- Patients experienced a low rate of symptomatic hypotension. The rates are comparable to placebo (VERQUVO 9.1% vs. Placebo 7.9%).1
- Consistent safety profile in patients with Type 2 Diabetes, impaired renal function (eGFR > 15mL/min/1.73m2), atrial fibrillation and coronary heart disease, as well as in patients who have been treated with other HF therapies.1
- Almost 95% of patients stayed on the therapy throughout the study duration.1
- Discontinuation rates: VERQUVO 6.8% vs. placebo 6.1%
Especially after a worsening HF event, patients need your protection.
Reference list:
- Armstrong, PW et al. Vericiguat in patients with heart failure and reduced ejection fraction. N Engl J Med. 2020; 382:1883-1893. Return to content
© Bayer AG 2021
This web page contains information on Verquvo which is based on the Summary of Product Characteristics (SPC) as approved by the European Commission. It is intended to provide information to an international audience outside the US and UK.
- PP-VER-ALL-0172-2
